Effect of conjugation methodology on the immunogenicity and protective efficacy of meningococcal group C polysaccharide-P64k protein conjugates

FEMS Immunology and Medical Microbiology

Volumn 40, Issue 3, 2004, Pages 193-199

  Carmenate, Tania ^a   Canaán, Leonardo ^a   Álvarez, Anabel ^a   Delgado, Maité ^a   González, Sonia ^a   Menéndez, Tamara ^a   Rodés, Lorenzo ^a   Guillén, Gerardo ^a  

^a CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

Author keywords

Meningococcal vaccine; Neisseria meningitidis; Polysaccharide conjugate

Indexed keywords

ADIPIC ACID; BACTERIAL POLYSACCHARIDE; CARRIER PROTEIN; CYANAMIDE; HYDRAZIDE DERIVATIVE; PROTEIN P64K; UNCLASSIFIED DRUG;

AMINATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; CONJUGATION; CONTROLLED STUDY; EVALUATION; FEMALE; IMMUNE RESPONSE; IMMUNOGENICITY; MOLECULAR WEIGHT; MOUSE; NEISSERIA MENINGITIDIS; NONHUMAN; POLYMERIZATION; PRIORITY JOURNAL; SEROTYPE; STATISTICAL ANALYSIS; T LYMPHOCYTE;

ADIPIC ACIDS; AMINATION; ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; CARBODIIMIDES; COLONY COUNT, MICROBIAL; DISEASE MODELS, ANIMAL; IMMUNOGLOBULIN G; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; MICE; MICE, INBRED BALB C; MOLECULAR WEIGHT; NEISSERIA MENINGITIDIS, SEROGROUP C; POLYSACCHARIDES, BACTERIAL; RATS; VACCINES, CONJUGATE;

EID: 1642341442     PISSN: 09288244     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0928-8244(03)00346-8     Document Type: Article

References (36)

1. Goldschneider I., Artenstein M.S. Human immunity to the meningococcus. IV. Immunogenicity of group A and group C meningococcal polysaccharide in human volunteers. J. Exp. Med. 129:1969;1367-1384.
2. Gold R., Lepow M.L., Goldschneider I., Draper T.F., Gotschlich E.C. Clinical evaluation of group A and group C meningococcal polysaccharide vaccines in infants. J. Clin. Invest. 56:1975;1536-1547.
3. Gold R., Lepow M.L., Goldschneider I., Draper T.F., Gotschlich E.C. Kinetics of antibody production to group A and group C meningococcal polysaccharide vaccines administered during the first six years of life: prospects for routine immunization of infants and children. J. Infect. Dis. 140:1979;690-697.
4. Jennings H., Lugowski C. Immunochemistry of groups A, B, and C meningococcal polysaccharide-tetanus toxoid conjugates. J. Immunol. 127:1981;1011-1018.
5. Slack M.P., Azzopardi H.J., Hargreaves R.M., Ramsay M.E. Enhanced surveillance of invasive Haemophilus influenzae disease in England, 1990 to 1996: impact of conjugate vaccine. Pediatr. Infect. Dis. 7:1998;S204-S207.
6. Murphy T.V., Pastor P., Medley F., Osterholm M.T., Granoff D.M. Decreased Haemophilus colonization in children vaccinated with Haemophilus influenzae type b conjugate vaccine. J. Pedriatr. 122:1993;517-523.
7. Peltola H. Meningococcal disease still with us. Rev. Infect. Dis. 5:1983;71-91.
8. MacDonald N.E., Halperin S.A., Law B.J., Forrest B., Danzig L.E., Granoff D.M. Induction of immunologic memory by conjugated vs plain meningococcal C polysaccharide vaccine in toddlers: a randomized controlled trial. J. Am. Med. Assoc. 280:1998;1685-1689.
9. Steinoff, M.C., Lewin, E.C., Gotschlich, E.C., Robbinns, J.B., Panorama Pedriatic Group (1981) Group C Neisseria meningitidis variant polysaccharide vaccines in children. Infect. Immun. 34, 114-146.
10. Arakere G., Frasch C.E. Specificity of antibodies to o-acetyl-positive and o-acetyl-negative group C meningococcal polysaccharides in sera from vaccines and carriers. Infect. Immun. 59:1991;4349-4356.
11. Gold R., Lepow M.L., Goldschneider I., Draper T.L., Gotschlich E.C. Clinical evaluation of group A and group C meningococcal polysaccharide vaccines in infants. J. Clin. Invest. 56:1975;1536-1547.
12. Richmond P., Kaczmarski E., Borrow R., Findlow J., Clark S., McCann R., Hill J., Barker M., Miller E. Meningococcal C polysaccharide vaccine induces immunologic hyporesponsiveness in adults that is overcome by meningococcal C conjugate vaccine. J. Infect. Dis. 181:2000;761-764.
13. Guillén G., Álvarez A., Silva R., Morera V., González S., Musacchio A., Besada V., Coizeau E., Caballero E., Nazábal C., Carmenate T., González L.J., Estrada R., Támbara Y., Padrón G., Herrera L. Expression in Escherichia coli of the lpdA gene, protein sequence analysis and immunological characterization of the P64k protein from Neisseria meningitidis. Biotechnol. Appl. Biochem. 27:1998;189-196.
14. Silva, R., Selman, H., Guillén, G., Herrera, L.S., Fernández, J.R., Novoa, L., Morera, V., González, S., Tamargo, B. et al. (1994) U.S. Patent 5,286,484.
15. Perez A., Dickinson F., Cinza Z., Ruiz A., Serrano T., Sosa J., González S., Gutiérrez Y., Nazábal C., Gutiérrez O., Guzmán D., Diaz M., Delgado M., Caballero E., Sardinas G., Álvarez A., Martín A., Guillen G., Silva R. Safety and preliminary immunogenicity of the recombinant outer membrane protein P64k of Neisseria meningitidis in human volunteers. Biotechnol. Appl. Biochem. 34:2001;121-125.
16. González S., Álvarez A., Caballero E., Viña L., Guillen G., Silva R. P64k meningococcal protein as immunological carrier for weak immunogens. Scand. J. Immunol. 52:2000;113-116.
17. Beuvery E.C., Miedema F., van Delft R.W., Haverkamp J., Leussink A.B., te Pas B.J., Teppema K.S. Preparation and physicochemical and immunological characterization of polysaccharide-outer membrane protein complexes of Neisseria meningitidis. Infect. Immun. 40:1983;369-380.
18. Wessels M.R., Paoletti L.C., Kasper D.L., DiFabio J.L., Michon F., Holme K., Jennings H. Immunogenicity in animals of a polysaccharide-protein conjugate vaccine against type III group B Streptococcus. J. Clin. Invest. 86:1990;1428-1433.
19. Colorimetric assays of sugar. Methods Enzymol. 3, 73-105.
20. Smith P.K., Krohn R.I., Hermanson G.T., Mallia A.K., Gartner F.H., Provenzano M.D., Fujimoto E.K., Goeke N.M., Olson B.J., Klenk D.C. Measurement of protein using bicinchoninic acid. Anal. Biochem. 150:1985;76-85.
21. Hedman K., Lappalainen M., Seppålå J., Mäkelä O. Recent primary toxoplasma infection indicated by low avidity of specific IgG. J. Infect. Dis. 159:1989;736-740.
22. Høiby E.A., Rosenqvist E., Froholm L.O., Bjune G., Feiring B., Nokleby H., Ronnild E. Bactericidal antibodies after vaccination with the Norwegian meningococcal vaccine. NIPH Ann. 14:1991;147-156.
23. Maslanka S.E., Gheesling L.L., Libutti D.E., Donaldson K.B., Harakeh H.S., Dykes J.K., Arhin F.F., Devi S.J., Frasch C.E., Huang J.C., Kriz-Kuzemenska P., Lemmon R.D., Lorange M., Peeters C.C., Quataert S., Tai J.Y., Carlone G.M. Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group. Clin. Diagn. Lab. Immunol. 2:1997;156-167.
24. Saukkonen K. Experimental meningococcal meningitis in the infant rat. Microb. Pathog. 3:1988;203-211.
25. Usinger W.R., Lucas A.H. Avidity as a determinant of the protective efficacy of human antibodies to pneumococcal capsular polysaccharide. Infect. Immun. 67:1999;2366-2370.
26. Granoff D.M. A modified enzyme-linked immunosorbent assay for measurement of antibody responses to meningococcal C polysaccharide that correlates with bactericidal responses. Clin. Diagn. Lab. Immunol. 5:1998;479-485.
27. Fattom A., Xiuru L., Hee Y., Burns A., Hawwari A., Shepherd E., Coughlin R., Winston S., Naso R. Effect of conjugation methodology, carrier protein, and adjuvants on the immune response to Staphylococcus aureus capsular polysaccharide. Vaccine. 13:1995;1288-1293.
28. Gupta R.K., Egan W., Bryla D., Robbins J.B., Szu S.C. Comparative immunogenicity of conjugates composed of Escherichia coli O111 O-specific polysaccharide, prepared by treatment with acetic acid or hydrazine, bound to tetanus toxoid by two synthetic schemes. Infect. Immun. 63:1995;2805-2810.
29. Schneerson R., Robbins J.B., Chu C., et al. Serum antibody responses of juvenile and infant rhesus monkeys injected with Haemophilus influenzae type b and pneumococcus type 6A polysaccharide-protein conjugates. Infect. Immun. 45:1984;582-591.
30. Sepal I., Micelle O. Antigenicity of dextran-protein conjugates in mice. Effect of molecular weight of the carbohydrate and comparison of two modes of coupling. J. Immunol. 143:1987;1259-1264.
31. Shen X., Lagergard T., Yang Y., Lindblad M., Fredriksson M., Holmgren J. Group D streptococcus capsular polysaccharide-cholera toxin B subunit conjugate vaccines prepared by different methods for intranasal immunization. Infect. Immun. 69:2001;297-306.
32. Anderson P.W., Pichichero M.E., Stein E.C., Porcelli S., Betts R.F., Connuck D.M., Korones D., Insel R.A., Zahradnik J.M., Eby R. Effect of oligosaccharide chain length, exposed terminal group, and hapten loading on the antibody response of human adults and infants to vaccines consisting of Haemophilus influenzae type b capsular antigen uniterminally coupled to the diphtheria protein CRM197. J. Immunol. 142:1989;2464-2468.
33. Wessels M.R., Paoletti L.C., Guttormsen H., Michon F., D'ambra A.J., Kasper D. Structural properties of group B streptococcal type III polysaccharide conjugate vaccines that influence immunogenicity and efficacy. Infect. Immun. 66:1998;2186-2192.
34. Dagan R., Eskola J., Leclerc C., Leroy O. Reduced response to multiple vaccines sharing common protein epitopes that are administered simultaneously to infants. Infect. Immun. 66:1998;2093-2098.
35. González S., Alvarez A., Caballero E., Viña L., Guillén G., Silva R. P64k meningococcal protein as immunological carrier for weak immunogens. Scand. J. Immunol. 52:2000;113-116.
36. Sardiñas G., González S., Garay H.E., Nazábal C., Reyes O., Silva R. Anti-PorA antibodies elicited by immunization with peptides conjugated to P64k. Biochem. Biophys. Res. Commun. 277:2000;51-54.